While it spent less last year, it is still a significant force, in shaping US health care and pharmaceutical and biotech legislation and regulations, thus:
. . .Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Policy matters related to Artificial Intelligence in health care; One Big Beautiful Bill Act (HR.1). . . .
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil; US Tariffs. . . .
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement pricing, coverage, value and access; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; One Big Beautiful Bill Act (HR.1). . . .
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value, access and quality. . . .
Pharmaceutical intellectual property issues; Implementation and extension of the Tax Cuts and Jobs Act; Domestic manufacturing tax incentives; Expensing of research and development costs; Global minimum tax; Pension and retirement benefit issues; round-tripping; One Big Beautiful Bill Act (HR.1). . . .
Hospital discounts; 340B program; Prescription drug value, access, quality and compliance with Drug Quality and Safety Act. . . .
Now you know. Onward -- as the malign cretin Greg Bovino tucks tail, and runs (like a coward) out of the City of Big Shoulders. Good Riddance, you lawless tear gasser -- of children!, and now. . . perjurer.
नमस्ते
No comments:
Post a Comment